Waltham drug maker Artisan Pharma Inc. has closed on $3 million in new equity funding according to federal documents. The latest funding brings the total raised by Artisan since it was founded in 2006 to $574.4 million.
While the documents filed with the U.S. Securities and Exchange Commission did not disclose specific backers in the new funding, Artisan’s previous investors include NGN Capital LLC, JAFCO American Ventures Inc., New Leaf Venture Partners Inc., Bio*One Capital Pte. Ltd. and NovaQuest Inc.
Artisan is focused on treating blood clotting disorders, and licensed from Japan-based Asahi Kasei Pharma Corp. a drug, ART-123, that is a human thrombomodulin being developed for the treatment of disseminated intravascular coagulation in sepsis and deep vein thrombosis. The drug won market approval for sales in Japan in January of 2008.
In January, Artisan raised $6 million in a tranche of debt and options financing as part of an overall $15.4 million round. It had originally filed the debt round at a cap of $11.2 million when it filed for the first tranche, worth $9.4 million, in April of 2009.